reMYND, Novo Nordisk Partner for Diabetes Treatment

reMYND and Novo Nordisk have entered into a license agreement to further develop reMYND’s ReS39 therapeutic treatment for diabetes. This program holds also promise for NASH and the metabolic syndrome.  

ReS39 sustains and increases the endogenous insulin production capacity of the pancreas by restoring beta-cell function and insulin signalling in Type 1 and Type 2 diabetes animal models.

Koen De Witte, managing director of reMYND, said,  “Diabetes patients would greatly benefit from restoring durably their endogenous insulin production and/or increasing insulin sensitivity. Novo Nordisk’s agility to step-in once they observed the effects of our ReS39 treatment in their own hands makes the road ahead all the more exciting.”

Under the agreement, reMYND could receive up to 350 million Euros in research and milestone payments, plus royalties on resulting net sales.